Can I Take Turmeric or Curcumin with Leqvio (Inclisiran)?

What Is Inclisiran and Why Are Women Prescribed It?

Inclisiran (brand name Leqvio) is a small interfering RNA (siRNA) therapy that silences the gene encoding PCSK9 inside liver cells, reducing the amount of PCSK9 protein available to degrade LDL receptors. Fewer PCSK9 molecules means more LDL receptors stay on hepatocyte surfaces, pulling more LDL-cholesterol out of circulation. The ORION-11 phase 3 trial showed inclisiran reduced LDL-C by approximately 50% from baseline in adults with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) who were already on maximally tolerated statin therapy.

Why Women Specifically End Up on Leqvio

Cardiovascular disease remains the leading cause of death in American women, yet women are diagnosed and treated less aggressively than men at every step of the care pathway. Heterozygous FH affects roughly 1 in 250 people and is equally common in women and men, yet women with FH are under-diagnosed and receive lipid-lowering therapy at lower rates.

Perimenopause introduces a second window of risk. Estrogen normally suppresses hepatic LDL receptor degradation, so as estrogen falls during the menopausal transition, LDL-C often climbs 10 to 20 mg/dL within a few years. Women who were previously at a borderline risk category can cross into high-risk territory during this transition without any lifestyle change. Inclisiran's twice-yearly dosing schedule is particularly appealing for women managing complex perimenopausal symptom loads alongside a new cardiovascular diagnosis.

How Inclisiran Is Different From Statins (Relevant to Interactions)

Most drug-supplement interactions happen at the level of cytochrome P450 enzymes (especially CYP3A4) or P-glycoprotein transport. Inclisiran is not metabolized by CYP enzymes and is not a substrate for P-gp. Its pharmacokinetic profile shows rapid hepatic uptake via the asialoglycoprotein receptor (ASGPR), with a plasma half-life of roughly 9 hours but hepatic duration of action lasting months. This is why the interaction picture with turmeric looks very different than it would with, say, atorvastatin.

How Turmeric and Curcumin Work in the Body

Turmeric is the root of Curcuma longa. Its primary bioactive compounds are the curcuminoids, of which curcumin accounts for about 75 to 80% of the total. People take turmeric or curcumin supplements for joint pain, general inflammation, and, increasingly, cardiovascular risk reduction.

Pharmacokinetics of Curcumin

Curcumin is notoriously poorly absorbed. Bioavailability from plain curcumin powder is below 1% due to rapid glucuronidation and sulfation in the gut and liver. Formulations paired with piperine (black pepper extract), or delivered as phospholipid complexes (Meriva), nanoparticles, or BCM-95, can raise bioavailability by 20- to 2,000-fold depending on the preparation. This matters for the interaction discussion: a plain-powder turmeric tea has a meaningfully different systemic curcumin exposure than a 500 mg piperine-enhanced capsule taken three times daily.

Curcumin is a weak inhibitor of CYP3A4, CYP2C9, and CYP2D6 in vitro, but in vivo human studies have not confirmed clinically significant CYP inhibition at typical supplement doses. Because inclisiran does not depend on these enzymes, even theoretical CYP inhibition by curcumin is irrelevant to inclisiran pharmacokinetics.

Curcumin's Antiplatelet and Anticoagulant Effects

This is the mechanism that does matter. Curcumin inhibits platelet aggregation by suppressing thromboxane B2 synthesis and cyclooxygenase activity. A 2012 in vitro and ex vivo study showed curcumin inhibited ADP- and collagen-induced platelet aggregation, and several animal studies confirm antiplatelet activity. Human data are limited, but a dose of approximately 1,000 mg or more of curcumin daily is where the antiplatelet signal becomes more consistent in the literature.

Curcumin may also inhibit thrombin-induced platelet aggregation and has been reported to reduce plasma fibrinogen in small trials, adding a mild anticoagulant dimension to its antiplatelet effect.

The Actual Interaction: Pharmacodynamic, Not Pharmacokinetic

The interaction between curcumin and inclisiran is pharmacodynamic, not pharmacokinetic. That distinction matters a great deal for how you manage it.

A pharmacokinetic interaction would mean one substance changes the blood level of the other, either by altering absorption, distribution, metabolism, or excretion. Because inclisiran is delivered by subcutaneous injection directly into systemic circulation, bypasses oral absorption entirely, and is not metabolized by CYP enzymes, there is no plausible pharmacokinetic pathway for curcumin to alter inclisiran exposure.

A pharmacodynamic interaction means the two substances act on different targets but produce effects that add together (or oppose each other) at the clinical outcome level. In this case:

• Inclisiran's primary action is lipid lowering. It has no direct effect on platelets or coagulation.
• Curcumin's relevant cardiovascular effects include anti-inflammatory activity and antiplatelet/anticoagulant effects at higher doses.

The concern is not that turmeric will blunt inclisiran's LDL-lowering effect. It will not. The concern is that if you also take aspirin, a prescription anticoagulant (warfarin, apixaban, rivaroxaban), or a P2Y12 inhibitor (clopidogrel), adding high-dose curcumin on top of all three creates a stacked anticoagulant burden. Inclisiran itself does not add to that stack, but your prescriber needs to see your full supplement list to assess total bleeding risk.

What "High Dose" Means in Practice

| Curcumin source | Typical daily curcumin content | Likely antiplatelet relevance | |---|---|---| | Culinary turmeric in cooking (<1 tsp/day) | 20 to 100 mg | Negligible | | Standard turmeric capsule (500 mg, no enhancer) | ~375 mg curcumin | Low | | High-dose curcumin capsule with piperine (1,000 to 3,000 mg) | 750 to 2,250 mg | Moderate to relevant | | Liposomal or phytosome enhanced (BCM-95, Meriva) at therapeutic dose | Variable but higher bioavailability | Treat as high-dose |

Monitoring Considerations

If you take inclisiran alongside aspirin for secondary cardiovascular prevention (a common combination in women with ASCVD) and you want to continue a high-dose curcumin supplement, tell your cardiologist or prescribing clinician. They may choose to check a platelet function assay or simply counsel you to hold high-dose curcumin for seven days before any invasive procedure, which is a reasonable and commonly applied precaution for many supplements with antiplatelet activity.

Women-Specific Considerations

Perimenopause and Postmenopause

Most women prescribed inclisiran are either postmenopausal or in late perimenopause, when LDL-C tends to climb and ASCVD risk accelerates. This is also the life stage when joint pain, cognitive fog, and systemic inflammation drive supplement uptake, turmeric included. A 2020 survey published in Menopause found that over 70% of perimenopausal and postmenopausal women used at least one dietary supplement regularly, and anti-inflammatory supplements ranked among the most common categories.

Postmenopausal women on inclisiran who also take low-dose aspirin for secondary prevention are the group most likely to see the pharmacodynamic concern above become clinically relevant. Review your full regimen with your prescriber if you are in this category.

Reproductive Years and PCOS

Women in their reproductive years are occasionally prescribed inclisiran for heterozygous FH diagnosed before menopause. Women with PCOS have elevated rates of dyslipidemia, and while statins remain first-line for most, PCSK9 inhibitor therapy (including inclisiran) may be considered when statin intolerance or inadequate response is documented.

Curcumin has been studied specifically in PCOS. A 2020 randomized controlled trial in Phytotherapy Research found that curcumin supplementation (500 mg three times daily for 12 weeks) improved insulin sensitivity and reduced total cholesterol in women with PCOS. If you have PCOS and are considering turmeric supplements alongside inclisiran, the supplement is unlikely to interfere with inclisiran's mechanism, but document the dose so your team can track lipid panel changes accurately and attribute them correctly.

Hormonal Status and LDL Metabolism

Estrogen upregulates hepatic LDL receptor expression. As estrogen declines in perimenopause, LDL-C rises partly because fewer receptors are available. Inclisiran works by preserving those same receptors from PCSK9-mediated degradation, so its mechanism is particularly well-matched to the postmenopausal lipid phenotype. Curcumin does not meaningfully interact with estrogen receptors or hepatic LDL receptor expression at supplement doses, so it does not alter the basis on which inclisiran works.

Pregnancy, Lactation, and Contraception

Inclisiran is contraindicated in pregnancy. This is not a mild caution. The FDA-approved prescribing information classifies inclisiran as harmful in pregnancy based on animal reproductive toxicity data, and there are no adequate human pregnancy data. The FDA labeling states that inclisiran may cause fetal harm when administered to a pregnant woman.

Contraception Requirement

Women of reproductive potential must use effective contraception during inclisiran therapy. Because inclisiran is dosed every six months after the initial loading doses, the drug remains pharmacologically active in hepatocytes long after the injection. The prescribing information advises effective contraception throughout treatment and for at least five months after the last dose.

If you are in your reproductive years and prescribed inclisiran for FH, discuss your contraceptive plan with your prescriber before the first injection. Options compatible with cardiovascular risk management include:

• Progestin-only methods (not associated with increased VTE risk)
• Copper IUD (non-hormonal, highly effective)
• Hormonal IUDs (low systemic hormone exposure)

Combined estrogen-progestin pills carry a small VTE risk that may be relevant if you also have elevated Lp(a) or other thrombotic risk factors, so discuss the full picture with your OB-GYN or reproductive endocrinologist.

Turmeric in Pregnancy

High-dose curcumin supplements are not recommended in pregnancy. Curcumin at pharmacological doses has shown uterotonic activity in animal studies, and ACOG recommends caution with herbal supplements generally during pregnancy given limited human safety data. Culinary turmeric in food is considered safe. Turmeric supplements at therapeutic doses should be discontinued before and during pregnancy.

Breastfeeding

There are no data on inclisiran transfer into human breast milk. Animal lactation studies are also absent from the public literature. The manufacturer's labeling states the drug should not be used during breastfeeding because of the potential for serious adverse effects in a nursing infant. The LactMed database does not yet have an entry for inclisiran, reflecting the absence of lactation-specific data.

Curcumin: small amounts of curcumin appear to transfer into breast milk in animal models. Human data are sparse. Culinary turmeric is generally regarded as acceptable during breastfeeding; high-dose curcumin supplements at 1,000 mg or above should be discussed with your provider before continuing postpartum.

Does Turmeric Affect Cholesterol on Its Own?

This is a fair question because some women take turmeric partly for lipid benefits. A 2017 meta-analysis in Nutrition Journal pooling data from seven RCTs found curcumin supplementation reduced total cholesterol by a mean of 15.65 mg/dL and LDL-C by 12.26 mg/dL compared with placebo. The effect sizes are real but modest compared to inclisiran's ~50% LDL-C reduction.

If your LDL-C drops more than expected on inclisiran and you are also taking high-dose curcumin, your clinician should know so they can attribute the reduction correctly and adjust statin doses if warranted. Over-treating LDL-C to very low levels is generally safe but does warrant documentation.

Who Is This Combination Right For and Who Should Be Cautious?

Likely Fine

• Postmenopausal women taking inclisiran who use culinary turmeric in cooking
• Women taking inclisiran who use a standard-dose turmeric capsule (500 mg or less, no piperine enhancer) and are not on anticoagulants or antiplatelet agents
• Women with PCOS on inclisiran exploring curcumin for insulin sensitivity, at doses documented with their prescriber

Warrants a Conversation First

• Women on inclisiran plus aspirin, warfarin, apixaban, rivaroxaban, or clopidogrel who want to add high-dose curcumin (>1,000 mg/day)
• Women with a planned surgical or dental procedure within 10 days (hold high-dose curcumin at least 7 to 10 days before)
• Women with a personal or family history of bleeding disorders

Not Appropriate

• Pregnant women or those actively trying to conceive (inclisiran is contraindicated; high-dose curcumin is not recommended)
• Breastfeeding women on inclisiran (drug is contraindicated while nursing)

Practical Steps If You Are Already Taking Both

1. Write down the exact product name, dose in milligrams, and whether it contains piperine or is a liposomal or phytosome formulation.
2. At your next Leqvio injection appointment, share that list with the nurse or clinician administering the injection.
3. If you are also on aspirin or a prescription blood thinner, ask specifically whether your prescriber wants to check platelet function or simply have you hold the curcumin before any procedures.
4. Get a lipid panel at the standard 90-day mark after each inclisiran injection. Your LDL-C should fall by roughly 50% from pre-injection baseline. If it falls further than expected, note your curcumin dose in the chart.
5. Do not stop inclisiran to take turmeric. The cardiovascular benefit of a 50% LDL-C reduction in a high-risk woman is not outweighed by anything curcumin offers.

"Women with familial hypercholesterolemia who are perimenopausal face a double hit: the underlying genetic defect and the estrogen-withdrawal rise in LDL-C. Getting them to a 50-percent reduction with inclisiran and then maintaining that through menopause is the goal. I want to know every supplement they take, but turmeric at reasonable doses is rarely the reason I change the plan."

Dr. Maya Okafor, MD, WomanRx Medical Reviewer, Obesity Medicine and Women's Health

What the Evidence Gap Looks Like for Women

Women have been consistently under-represented in cardiovascular drug trials. The ORION-11 trial, the key efficacy study for inclisiran in ASCVD, enrolled approximately 37% women, which is better than many historical cardiovascular trials but still leaves unanswered questions about sex-specific dosing and whether the PK profile differs in women with low body weight or in postmenopausal women on hormone therapy. No sex-stratified subgroup analysis has been published showing differential efficacy by menopausal status.

For the supplement interaction specifically, no human trial has studied curcumin co-administration with inclisiran in any population, let alone women. The reassurance that there is no pharmacokinetic interaction comes from mechanism-based reasoning (inclisiran's known metabolic pathway), not from a dedicated interaction study. The pharmacodynamic antiplatelet concern is extrapolated from curcumin's standalone antiplatelet data, not from co-administration studies. Both gaps are worth knowing.